Company Overview

Update
Founded:
2010
Founders:
Stephane Bancel, Robert S. Langer, Noubar Afeyan
Headquarters:
Cambridge
Funding:
$224.6M
Categories:
Biotechnology
Description:
Moderna Therapeutics develops messenger RNA therapeutics that produces human proteins for antibodies inside patient cells.

Detailed Description

Update

Moderna is pioneering messenger RNA therapeutics™, an entirely new in vivo drug modality that produces human proteins or antibodies inside patient cells, which are in turn active intracellularly or secreted. This breakthrough platform addresses currently undruggable targets, and offers a superior alternative to existing drug modalities for a wide range of disease conditions.

Moderna has developed a broad intellectual property estate including more than 250 patent applications covering novel nucleotide chemistries and drug compositions. The company plans to develop and commercialize its innovative mRNA drugs through a combination of strategic relationships as well as new formed ventures.

Founded in late 2010 by Flagship VentureLabs, Cambridge-based Moderna is privately held and currently has strategic agreements with AstraZeneca and Alexion Pharmaceuticals.

Current Team (9)

Update

Past Team (1)

Update

Funding Rounds (4) - $224.6M

Update

Investments (1)

Update

Board Members and Advisors (5)

Update

Investors (2)

Update

Offices/Locations (2)

Update
  • Headquarters

    320 Bent Street

    Cambridge, 02141

  • Office

    200 Tech Street

    Cambridge, MA 02139

    USA

Images (1)

Update
  • Ffc535abaf80df2547b5faf57707f487